Company Description
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-ĸβ pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors.
It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA.
Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.
The company was incorporated in 2013 and is based in Los Angeles, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Sep 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | John Yu |
Contact Details
Address: 2355 Westwood Boulevard, Suite 139 Los Angeles, California 90064 United States | |
| Phone | 310-948-2356 |
| Website | kairospharma.com |
Stock Details
| Ticker Symbol | KAPA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001962011 |
| ISIN Number | US48301N1046 |
| Employer ID | 46-2993314 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John S. Yu M.D., Ph.D. | Chief Executive Officer, Chairman and Secretary |
| Douglas W. Samuelson C.P.A. | Chief Financial Officer |
| Dr. Neil A. Bhowmick Ph.D. | Chief Scientific Officer |
| Dr. Ramachandran Murali Ph.D. | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | 10-K/A | [Amend] Annual report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | 424B3 | Prospectus |
| Apr 24, 2025 | EFFECT | Notice of Effectiveness |
| Apr 24, 2025 | 8-K | Current Report |
| Apr 22, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 15, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 20, 2025 | 8-K | Current Report |